Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Angela Q. Qu"'
Autor:
Angela Q. Qu, Yu-Ning Wong, Guru Sonpavde, Guenter Niegisch, Matthew D. Galsky, Robert Dreicer, Jonathan E. Rosenberg, Srikala S. Sridhar, Ashley Marie Regazzi, Giuseppe Di Lorenzo, Yu-Hui Chen, Gregory R. Pond, Andrea Necchi, Joaquim Bellmunt, Matthew I. Milowsky, Ronan Fougeray, Dean F. Bajorin, Peter Albers, Toni K. Choueiri, Yoo Joung Ko
Publikováno v:
Clinical Genitourinary Cancer. 13:185-192
In this retrospective analysis, complete remission (CR) of disease occurred in 1.8% of patients receiving salvage systemic therapy for advanced urothelial carcinoma. CR was strongly associated with longer survival, prior cisplatin therapy, and time f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24c66a11c57adc667c36fe630f37f9e1
https://doi.org/10.1016/j.clgc.2014.09.004
https://doi.org/10.1016/j.clgc.2014.09.004
Autor:
Peter H. O'Donnell, Ulka N. Vaishampayan, Guenter Niegisch, Peter Albers, Yu-Ning Wong, Nicholas D. James, Joaquim Bellmunt, Toni K. Choueiri, Gregory R. Pond, Angela Q. Qu, Srikala S. Sridhar, Guru Sonpavde, David J. Vaughn, Ronan Fougeray, Walter M. Stadler, Daniel P. Petrylak, Jonathan E. Rosenberg, Cora N. Sternberg, Tomasz M. Beer, Awais M. Khan, Yoo Joung Ko, Matthew D. Galsky, Nicholas J. Vogelzang
Publikováno v:
European Urology. 63:717-723
Outcomes for patients in the second-line setting of advanced urothelial carcinoma (UC) are dismal. The recognized prognostic factors in this context are Eastern Cooperative Oncology Group (ECOG) performance status (PS)0, hemoglobin level (Hb)10 g/dl,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdde7df6527370269d7fbb3585629ac7
https://doi.org/10.1016/j.eururo.2012.11.042
https://doi.org/10.1016/j.eururo.2012.11.042
Autor:
Angela Q. Qu, Guru Sonpavde, Toni K. Choueiri, Andrea Necchi, Gregory R. Pond, Joaquim Bellmunt, Stephanie A. Mullane, Giuseppe Di Lorenzo, Jonathan E. Rosenberg, Piera Federico
Publikováno v:
Clinical genitourinary cancer. 13(3)
In this retrospective study, docetaxel treatment after previous paclitaxel treatment and the reverse sequence demonstrated outcomes and activity similar to salvage therapy for advanced urothelial carcinoma (UC). The clinical implications are that tri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c309397198b01289379b75cebd394cbf
https://pubmed.ncbi.nlm.nih.gov/25481485
https://pubmed.ncbi.nlm.nih.gov/25481485
Autor:
Yu-Ning Wong, Joaquim Bellmunt, Dean F. Bajorin, Guenter Niegisch, Guru Sonpavde, Matthew D. Galsky, Andrea Necchi, Ashley Marie Regazzi, Srikala S. Sridhar, Gregory R. Pond, Ronan Fougeray, Angela Q. Qu, Peter Albers, Toni K. Choueiri, Jonathon E. Rosenberg, Yoo Joung Ko, Matthew I. Milowsky, Giuseppe Di Lorenzo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bd2a49b7e88925a0df4ce1b49cf6a0d
Autor:
Srikala S. Sridhar, Yu-Ning Wong, Neeraj Agarwal, Kenneth M. Boucher, Daniel P. Petrylak, Joaquim Bellmunt, Srinivas K. Tantravahi, Ronan Fougeray, Benjamin L. Maughan, Guru Sonpavde, Tomasz M. Beer, Cora N. Sternberg, Matthew D. Galsky, Jonathan E. Rosenberg, Amitkumar Mehta, Yoo Joung Ko, Peter Albers, Angela Q. Qu, Toni K. Choueiri, Ulka N. Vaishampayan, Guenter Niegisch, Nicholas J. Vogelzang
Publikováno v:
Clinical genitourinary cancer. 12(2)
Objective Second-line systemic therapy for advanced urothelial carcinoma (UC) has substantial unmet needs, and current agents show dismal activity. Second-line trials of metastatic UC have used response rate (RR) and median progression-free survival
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c34715747f11f14f04b01a616b9c53a
https://pubmed.ncbi.nlm.nih.gov/24220220
https://pubmed.ncbi.nlm.nih.gov/24220220
Autor:
Neeraj Agarwal, Angela Q. Qu, Matthew D. Galsky, Andrea Necchi, Guru Sonpavde, Guenter Niegisch, Gregory R. Pond, Joaquim Bellmunt, Yacine Salhi, Ronan Fougeray, Peter Albers, Toni K. Choueiri, Giuseppe Di Lorenzo
Publikováno v:
Clinical genitourinary cancer. 11(4)
In a retrospective analysis of pooled phase II trials, best prior response in patients receiving prior chemotherapy for metastatic disease did not confer an independent prognostic impact with second-line therapy for advanced urothelial carcinoma. Bac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::698ccdcd8fde156aab045bf4dde35abe
https://pubmed.ncbi.nlm.nih.gov/23800847
https://pubmed.ncbi.nlm.nih.gov/23800847
Autor:
Joaquim Bellmunt, Ashley Marie Regazzi, Yoo-Joung Ko, Matthew D. Galsky, Yu-Ning Wong, Guru Sonpavde, Andrea Necchi, Dean F. Bajorin, Matthew I. Milowsky, Giuseppe Di Lorenzo, Srikala S. Sridhar, Gregory R. Pond, Angela Q. Qu, Jonathan E. Rosenberg, Ronan Fougeray, Guenter Niegisch, Peter Albers, Toni K. Choueiri
Publikováno v:
Journal of Clinical Oncology. 32:353-353
353 Background: The prognostic impact of number of lines of prior chemotherapy and prior perioperative chemotherapy on survival results in salvage trials for advanced UC is unknown. Methods: We pooled 10 prospective phase II trials of salvage therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c1b29b75e5dae7a76a036e1dfb8e314e
https://doi.org/10.1200/jco.2014.32.4_suppl.353
https://doi.org/10.1200/jco.2014.32.4_suppl.353
Autor:
Giuseppe Di Lorenzo, Yu-Ning Wong, Andrea Necchi, Matthew I. Milowsky, Joaquim Bellmunt, Guenter Niegisch, Srikala S. Sridhar, Yoo-Joung Ko, Gregory R. Pond, Peter Albers, Ronan Fougeray, Matthew D. Galsky, Toni K. Choueiri, Angela Q. Qu, Ashley Marie Regazzi, Jonathan E. Rosenberg, Dean F. Bajorin, Guru Sonpavde
Publikováno v:
Journal of Clinical Oncology. 32:336-336
336 Background: The prognostic impact of prior platinum agent (cisplatin vs. carboplatin) and site of primary (bladder vs. other) in the context of salvage therapy for advanced UC is unknown. Methods: We pooled 10 prospective phase II trials of ≥ s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ea783376e08f6663fe8ae0b028eee56d
https://doi.org/10.1200/jco.2014.32.4_suppl.336
https://doi.org/10.1200/jco.2014.32.4_suppl.336
Autor:
David J. Vaughn, Walter M. Stadler, Yoo-Joung Ko, Guru Sonpavde, Matthew D. Galsky, Peter H. O'Donnell, Neeraj Agarwal, Gregory R. Pond, Nicholas J. Vogelzang, Peter Albers, Yacine Salhi, Toni K. Choueiri, Joaquim Bellmunt, Angela Q. Qu, Srikala S. Sridhar, Cora N. Sternberg, Nicholas D. James, Yu-Ning Wong, Guenter Niegisch, Ronan Fougeray
Publikováno v:
Journal of Clinical Oncology. 31:4524-4524
4524 Background: Prognostic factors may impact on endpoints used in phase II trials of second-line therapy for advanced UC. We aimed to study the impact of prognostic factors (liver metastasis [LM], anemia [Hb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b3fc5ae8588631b2371fbbb478ace436
https://doi.org/10.1200/jco.2013.31.15_suppl.4524
https://doi.org/10.1200/jco.2013.31.15_suppl.4524
Autor:
Joaquim Bellmunt, Angela Q. Qu, Guru Sonpavde, Ronan Fougeray, Matthew D. Galsky, Guenter Niegisch, Gregory R. Pond, Peter Albers, Toni K. Choueiri, Yacine Salhi, Giuseppe Di Lorenzo, Andrea Necchi
Publikováno v:
Journal of Clinical Oncology. 31:4539-4539
4539 Background: Performance status (PS), hemoglobin (Hb), liver metastasis (LM), and time from prior chemotherapy (TFPC) are significant prognostic factors in second-line therapy for advanced UC. Setting of prior chemotherapy, i.e., metastatic or pe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eda47fefff7199758054b6517433e2de
https://doi.org/10.1200/jco.2013.31.15_suppl.4539
https://doi.org/10.1200/jco.2013.31.15_suppl.4539